Skip to content
18 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · story · 15 November – 18 November

AstraZeneca's Klygefa approved for myasthenia gravis in US and EU

AstraZeneca · 19 headlines from 17 outlets, from 15 November 2026 to 18 November 2026.

The story

+10.0strongly positive
Headlines19
Outlets17
Days315 November – 18 November

Outlets report Klygefa has won EU approval alongside its US approval for generalised myasthenia gravis.

Tone by day

Average of each day's headlines, −10 to +10.

Source: MarketFrame news analysis

Tone by day. Average of each day's headlines, −10 to +10. Source: MarketFrame news analysis
dayAverage tone
15 Nov10.0
17 Nov10.0
18 Nov10.0

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

How each outlet covered it · 17 outlets

The 10 outlets with the most impact on the tone

Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.

Source: MarketFrame news analysis

The 10 outlets with the most impact on the tone. Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone. Source: MarketFrame news analysis
outletAverage tone
Quantisnow10.0
Sharecast9.6
MLQ.ai10.0
PharmTech.com10.0
Zacks Investment Research10.0
FirstWord Pharma10.0
BioPharm International10.0
AllSci10.0
Yahoo Finance UK10.0
Securities.io10.0
OutletHeadlinesAverage tone
Quantisnow2+10.0
Sharecast2+9.6
MLQ.ai1+10.0
PharmTech.com1+10.0
Zacks Investment Research1+10.0
FirstWord Pharma1+10.0
BioPharm International1+10.0
AllSci1+10.0
Yahoo Finance UK1+10.0
Securities.io1+10.0
All 17 outlets
OutletHeadlinesAverage tone
MarketScreener1+10.0
StreetInsider1+10.0
AD HOC NEWS1+10.0
London South East1+10.0
Dealroom1+10.0
Traders Union1+9.2
Endpoints News1+5.0

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Day by day · 3 days, strongest headlines first

Wednesday 18 November 20262 headlines · Reports say Klygefa, a medicine for myasthenia gravis that patients inject themselves once a week, has been approved by the FDA and in the EU.+10.0
ToneWhat the article reported, and why it scored that waySource
+10.0US regulator clears new weekly self-injected rare disease drug.MLQ.ai (opens the article) ↗
+9.2Approvals in US and EU for new drug; gains in focus.Traders Union (opens the article) ↗
Tuesday 17 November 202616 headlines · Outlets report Klygefa has won EU approval alongside its US approval for generalised myasthenia gravis.+10.0
ToneWhat the article reported, and why it scored that waySource
+10.0Two US regulatory clearances for new uses and a new drug.PharmTech.com (opens the article) ↗
+10.0New drug cleared in both US and Europe.Zacks Investment Research (opens the article) ↗
+10.0Next-generation therapy cleared in both markets.FirstWord Pharma (opens the article) ↗
+10.0American regulator clears new generalised myasthenia treatment.BioPharm International (opens the article) ↗
+10.0Rare muscle disorder drug cleared in two regions.Sharecast (opens the article) ↗
+10.0Self-administered therapy cleared in US and Europe.AllSci (opens the article) ↗
+10.0European clearance for myasthenia treatment.Quantisnow (opens the article) ↗
+10.0Approvals secured on both sides of Atlantic.Yahoo Finance UK (opens the article) ↗
8 more headlines that day
ToneWhat the article reported, and why it scored that waySource
+10.0European clearance for myasthenia drug.Securities.io (opens the article) ↗
+10.0US clearance for myasthenia treatment.Quantisnow (opens the article) ↗
+10.0Adult myasthenia drug cleared in Europe.MarketScreener (opens the article) ↗
+10.0European clearance for myasthenia treatment.StreetInsider (opens the article) ↗
+10.0Transatlantic approvals for new drug lift outlook.AD HOC NEWS (opens the article) ↗
+10.0US and European clearance for autoimmune treatment.London South East (opens the article) ↗
+8.3Part of roundup noting approvals for its myasthenia asset.Sharecast (opens the article) ↗
+5.0Approval positive, but competition in the field is heavy.Endpoints News (opens the article) ↗
Sunday 15 November 20261 headline · Klygefa received FDA approval to treat generalised myasthenia gravis.+10.0
ToneWhat the article reported, and why it scored that waySource
+10.0US regulator clears new treatment for a rare muscle condition.Dealroom (opens the article) ↗

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 18 November · 867 headlines · 94 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt